Rinvoq

Dermatitis, Atopic, Dermatitis, Atopic, Rheumatoid Arthritis + 8 more
Treatment
8 FDA approvals
3 Active Studies for Rinvoq

What is Rinvoq

UpadacitinibThe Generic name of this drug
Treatment SummaryUpadacitinib is a medication used to treat rheumatoid arthritis, an autoimmune disease that causes inflammation in the joints. It works by blocking a protein known as Janus kinase (JAK) 1, which is believed to be involved in the body's immune response. Upadacitinib is taken orally and was approved by the FDA in 2019. It is marketed under the brand name RINVOQ™ and is also being studied to see if it can help treat other inflammatory conditions such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and at
Rinvoqis the brand name
image of different drug pills on a surface
Rinvoq Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Rinvoq
Upadacitinib
2019
3

Approved as Treatment by the FDA

Upadacitinib, also known as Rinvoq, is approved by the FDA for 8 uses like Ankylosing Spondylitis (AS) and moderate, refractory Atopic dermatitis .
Ankylosing Spondylitis (AS)
Used in combination with Ketorolac to help manage Ankylosing Spondylitis (AS)
moderate, refractory Atopic dermatitis
Used in combination with Halcinonide to help manage moderate, refractory Atopic dermatitis
inadequate response or intolerance to DMARDs
Used in combination with Ketorolac to help manage inadequate response or intolerance to DMARDs
Rheumatoid Arthritis
Used to treat Moderately to Severely Active Rheumatoid Arthritis in combination with Methotrexate
inadequate response to other therapeutic measures
Used in combination with Halcinonide to help manage inadequate response to other therapeutic measures
Dermatitis, Atopic
Used in combination with Halcinonide to help manage refractory, severe Atopic Dermatitis
Dermatitis, Atopic
Used in combination with Halcinonide to help manage moderate, refractory Atopic dermatitis
Ankylosing Spondylitis
Used in combination with Ketorolac to help manage Ankylosing Spondylitis (AS)

Effectiveness

How Rinvoq Affects PatientsUpadacitinib is a drug used to treat autoimmune inflammatory conditions such as rheumatoid arthritis. It works by blocking Janus Kinases, which are cell signals that trigger inflammation. In clinical studies, upadacitinib reduced inflammation-causing interleukins, increased the number of lymphocytes in the body, and slightly decreased levels of immunoglobulins.
How Rinvoq works in the bodyRheumatoid arthritis is a chronic autoimmune disorder caused by the interaction between immune cells and inflammatory chemicals. Janus Kinase (JAK) proteins are involved in this process by helping certain inflammatory chemicals activate their receptors. Upadacitinib blocks JAK proteins and stops these chemicals from causing inflammation. In studies, it was shown to stop the inflammation caused by chemicals like IL-6 and IL-7. By blocking JAK proteins, Upadacitinib prevents inflammation from developing in people with rheumatoid arthritis.

When to interrupt dosage

The advised dosage of Rinvoq is contingent upon the determined condition, for example Arthritis, Psoriatic, methotrexate and inadequate response to conventional therapy. The amount of dosage is contingent upon the technique of delivery featured in the table beneath.
Condition
Dosage
Administration
Rheumatoid Arthritis
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
inadequate response or intolerance to DMARDs
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Dermatitis, Atopic
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Dermatitis, Atopic
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Ankylosing Spondylitis
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Disease
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Colitis, Ulcerative
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
candidate for systemic therapy
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
inadequate response to other therapeutic measures
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Tumor Necrosis Factor Inhibitors
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral
Dermatitis, Atopic
15.0 mg, , 30.0 mg, 45.0 mg
, Tablet, extended release, Tablet, extended release - Oral, Oral

Warnings

Rinvoq Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Upadacitinib may interact with Pulse Frequency
There are 20 known major drug interactions with Rinvoq.
Common Rinvoq Drug Interactions
Drug Name
Risk Level
Description
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Upadacitinib.
Bleselumab
Major
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Bleselumab.
Cyclosporine
Major
Upadacitinib may increase the immunosuppressive activities of Cyclosporine.
Fasitibant
Major
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Fasitibant.
Inolimomab
Major
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Inolimomab.
Rinvoq Toxicity & Overdose RiskTaking too much upacitinib can cause adverse reactions, so it is important to monitor for signs and symptoms if an overdose occurs. It has been found that rats have a toxic dose of 14500mg/kg when given upacitinib orally.
image of a doctor in a lab doing drug, clinical research

Rinvoq Novel Uses: Which Conditions Have a Clinical Trial Featuring Rinvoq?

At present, there are 3 clinical trials assessing the capability of Rinvoq in providing relief from Methotrexate, Atopic Dermatitis and Ankylosing Spondylitis.
Condition
Clinical Trials
Trial Phases
Disease
0 Actively Recruiting
Rheumatoid Arthritis
0 Actively Recruiting
Dermatitis, Atopic
0 Actively Recruiting
Colitis, Ulcerative
0 Actively Recruiting
candidate for systemic therapy
0 Actively Recruiting
Tumor Necrosis Factor Inhibitors
0 Actively Recruiting
Dermatitis, Atopic
0 Actively Recruiting
inadequate response or intolerance to DMARDs
0 Actively Recruiting
inadequate response to other therapeutic measures
0 Actively Recruiting
Dermatitis, Atopic
0 Actively Recruiting
Ankylosing Spondylitis
3 Actively Recruiting
Phase 3, Not Applicable

Rinvoq Reviews: What are patients saying about Rinvoq?

5Patient Review
10/2/2021
Rinvoq for Rheumatoid Arthritis
Rinvoq has completely changed my quality of life for the better. I was struggling with pain from RA and PsA, and nothing was helping me. But this medication has reduced my pain by 90%. The only downside is some intestinal issues, but that has stabilized now.
5Patient Review
8/3/2021
Rinvoq for Rheumatoid Arthritis
I'm feeling a lot better since starting this medication, though I am more tired than usual and have noticed some bruising.
5Patient Review
6/4/2021
Rinvoq for Rheumatoid Arthritis
Rinvoq is my favorite medication. It really helps in the morning.
5Patient Review
5/31/2022
Rinvoq for Atopic Dermatitis
I noticed a difference in my skin after taking the first pill, and it continued to improve over the next few weeks. My eczema was severe before starting this medication, but it has helped immensely.
5Patient Review
7/31/2021
Rinvoq for Rheumatoid Arthritis
I don't know why my previous five-star review was changed to four stars, but I'm reposting this with the full rating.
View All Reviews
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about rinvoq

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Rinvoq a high risk medication?

"The FDA has issued warnings about serious side effects associated with Rinvoq, including infections, cancer, blood clots, cardiovascular problems, and increased risk of death."

Answered by AI

What is Rinvoq used to treat?

"The drug RINVOQ is used to treat moderate to severe rheumatoid arthritis in adults who have not responded well or are unable to tolerate other drugs known as tumor necrosis factor (TNF) blockers."

Answered by AI

Is Rinvoq and Humira the same?

"The ICER states that Rinvoq provides a small to substantial health benefit over Humira with a value-based price benchmark of $44,000 to $45,000 per year of treatment."

Answered by AI

Does Rinvoq have side effects?

"If you experience any of the following symptoms, you may be having an allergic reaction: rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat. Some of these reactions can be serious."

Answered by AI

Clinical Trials for Rinvoq

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top